A PYMNTS Company

UK: Newest pay-for-delay controversy plagues drugmaker leader

By  |  April 22, 2013

The largest drugmaker within Britain, GlaxoSmithKline, has been hit with the latest in a serious of multinational controversies regarding so-called pay-for-delay deals, used when drugmakers pay the producers of generic drugs to keep their products, often less expensive than brand-names, off the shelves. GSK had reportedly defended its business practices and denied any wrongdoing, but the Office of Fair Trading has accused the company of abusing its market dominance by paying the makers of the generic form of antidepressant Seroxat to delay the sale of their version of the drug. According to the OFT, GSK is accused of colluding with Alpharma, Gerics and Norton Healthcare over the supply of the drug about 10 years ago. The supply agreements were reportedly terminated in 2004. Similar investigations have been initiated within the US and Europe.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Euronews

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.